Glycosylated antitumor ether lipids: Activity and mechanism of action

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 4, 2014, Pages 592-606

  Arthur, Gilbert ^a   Bittman, Robert ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Anticancer activity; Antitumor ether lipids; Glycosylated antititumor ether lipids; Lysosomal mediated cell death; Mechanism of action; Synthesis

Indexed keywords

1 O (BETA D MALTOSYL) 3 O ALKYL SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 C (2 DEOXY BETA D GLUCOPYRANOSYL) SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 C (2 DEOXY BETA D GLUCOSAMINO) SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 O (2 AMINO 2 DEOXY BETA D GLUCOPYRANOSYL) SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 O (2 DEOXY ALPHA D ARABINO HEXOPYRANOSYL) SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 O (2 DEOXY BETA D ARABINO HEXOPYRANOSYL) SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 O (2 O ALPHA D MANNOPYRANOSYL) SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 O (2 O BETA D GLUCOPYRANOSYL) SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 O (2 O METHYL ALPHA D MANNOPYRANOSYL) SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 O (BETA D GLUCOPYRANOSYL) SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 O (BETA MALTOSYL) SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 S (ALPHA D 1 THIOGLUCOPYRANOSYL) SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 S (BETA D 1 THIOGLUCOPYRANOSYL) SN GLYCEROL; 1 O HEXADECYL 2 O OMETHYL 3 O (BETA D GLUCOPYRANOSYL) SN GLYCEROL; 1 O HEXADECYL 2 O OMETHYL 3 O (BETA D LACTOSYL) RAC GLYCEROL; 1 O HEXADECYL 2 OMETHYL 3 O (2 ACETAMIDO 2 DEOXY BETA D GLUCOPYRANOSYL) SN GLYCEROL; 1 O OCTADECYL 2 O METHYL 3 O (BETA D GLUCOPYRANOSYL) SN GLYCEROL; 1,2 DI O ACETYL 3,4,6 TRI O BENZYL BETA D GLUCOPYRANOSE; 2 DEOXY C GLYCOLIPID; 2' DEOXY BETA GLYCOSIDE; 2' METHOXY BETA GLYCOSIDE; 2,3 DIDEOXY C GLYCOLIPID; ALKYLLYSOPHOSPHOLIPID; ANTINEOPLASTIC AGENT; CATHEPSIN; DIDEOXY C GLYCOSIDE ANALOGUE; ETHER LIPID; MILTEFOSINE; OXO BM41 440; UNCLASSIFIED DRUG; UNINDEXED DRUG;

1 O (BETA D MALTOSYL) 3 O ALKYL SN GLYCEROL; ANTIHEMOLYSIS ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTITHROMBOGENIC ACTIVITY; APOPTOSIS; AUTOPHAGOSOME; CANCER GROWTH; CELL DEATH; CELL INVASION; CELL MOTILITY; CELL VIABILITY; CYTOTOXICITY; DNA DAMAGE; DRUG ACTIVITY; ENDOCYTOSIS; GLYCOSYLATION; HEMOLYSIS; HUMAN; HYDROGENOLYSIS; MACROAUTOPHAGY; NECROSIS; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CATHEPSINS; CELL DEATH; DRUG RESISTANCE, NEOPLASM; GLYCOSYLATION; HEMOLYSIS; HUMANS; NEOPLASMS; PHOSPHOLIPID ETHERS; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84897399896     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140309231144     Document Type: Review

References (137)

1. Ferguson, L.R.; Pearson, A.E. The clinical use of mutagenic anticancer drugs. Mut. Res., 1996, 355, 1.
2. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J, Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Eng. J. Med., 2001, 344, 783.
3. MacFarlane, M. Cell death pathways-potential therapeutic targets. Xenobiotica, 2009, 39, 616.
4. Wong, S.T.; Goodin, S. Overcoming drug resistance in patients with metastatic breast cancer. Pharmacotherapy, 2009, 29, 954.
5. Kruh, D.G. Introduction to resistance to anticancer agents. Oncogene, 2003, 22, 7262.
6. Dai, Y.; Lawrence, T.S.; Xu, L. Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am. J. Trans. Res., 2009, 1, 1.
7. Philchenkov, A.; Zaveecich, M.; Kroczak, T.J.; Los, M. Caspases and cancer: Mechanism of inactivation and new treatment modalities. Exp. Oncol., 2004, 26, 82.
8. Bedard, P.L.; Cardoso, F.; Piccart-Gebhart, M.J. Stemming resistance to HER-2 targeted therapy. J. Mammary Gland Biol. Neoplasia, 2009, 14, 55.
9. Longley, D.B.; Johnston, P.G. Molecular mechanisms of drug resistance. J. Pathol., 2005, 205, 275.
10. Fulda, S.; Pervaiz, S. Apoptosis signaling in cancer stem cells. Int. J. Biochem. Cell. Biol., 2010, 42, 31.
11. Soengas, M.S.; Capodieci, P.; Polsky, D.; Mora, J.; Esteller, M.; Opitz-Araya, X.; McCombie, R.; Herman, J.G.; Gerlad, W.L.; Lazebnik, Y.A.; Cordon-Cardo, C.; Lowe, S.W. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature, 2001, 409, 207.
12. Deming, P.B.; Schafer, Z.T.; Tashker, J.S.; Potts, M.B.; Deshmukh, M.; Kornbluth, S. Bcr-Abl-mediated protection from apoptosis downstream of mitochondria c release. Mol. Cell. Biol., 2004, 24, 10289.
13. Berdel, W.E.; Andreesen, R.; Munder, P.G. In Phospholipids and Cellular Regulation, Vol II, J.F. Kuo, Ed., CRC Press, Boca Raton, FL 1985, pp. 41-73.
14. Berdel, W.E. Membrane interactive lipids as experimental anticancer drugs. Br. J. Cancer, 1991, 64, 208.
15. Berdel, W.E.; Bausert, W.R.E.; Fink, U.; Rastetter, J.; Munder, P.G. Anti-tumor action of alkyllysophospholipids. Anticancer Res., 1981, 1, 345.
16. Honma, Y.; Kasukabe, T.; Hozumi, M.; Tsuhima, S.; Nomura, H. Induction of differentiation of cultured human and mouse myeloid leukemia cells by alkyl-lysophospholipids. Cancer Res., 1980, 41, 3211.
17. Smets, L.A.; Van Rooij, H.; Salmons, G.S. Signaling steps in apoptosis by ether lipids. Apoptosis, 1999, 4, 419.
18. Houlihan, W.J.; Lohmeyer, M.; Workman, P.; Cheon, S.H. Phospholipid antitumor agents. Med. Res. Rev., 1995, 15, 157.
19. Byun, H.S.; Bittman, R.; Samadder, P.; Arthur, G. Synthesis and antitumor activity of ether glycerol-phospholipids bearing a carbamate moiety at the sn-2 position: selective sensitivity against prostate cancer cell lines. Chem. Med. Chem., 2010, 5, 967.
20. Eibl, H.; Unger, C. Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat. Rev., 1990, 17, 233.
21. Sobottka, S.B.; Berger, M.R.; Eibl, H. Structure activity relationships of four anti-cancer alkyphosphocholine derivatives in vitro and in vivo. Int. J. Cancer, 1993, 53, 418.
22. Gills, J.J.; Dennis, P.A. Perifosine: update on a novel Akt inhibitor. Curr. Onc. Rep. 2009, 11, 102.
23. Bittman, R.; Arthur, G. Antitumor ether lipids: biological and biochemical effects in Liposomes: Rationale Design, A.S. Janoff, Ed., Marcell Dekker, New York 1999, pp. 125-144.
24. Danker, K.; Reutter, W.; Semini, G. Glycosidated phospholipids: uncoupling of signaling pathways at the plasma membrane. Br. J. Pharmacol, 2010, 160, 36.
25. Erukulla, R.K.; Zhou, X.; Samadder, P.; Arthur, G.; Bittman, R. Synthesis and evaluation of the antiproliferative effects of 1-O-hexadecyl-2-O-methyl-3-O-(2'-acetamido-2'-deoxy-p-D-glucopyranosyl)-sn-glycerol and 1-O-hexadecyl-2-O-methyl-3-O-(2'-amino-2'deoxy-(3-D-glucopyranosyl)-sn-glycerol on epithelial cancer cell growth. J. Med. Chem., 1996, 39, 1541.
26. Bartolmäs, T.; Heyn, T.; Mickeleit, M.; Fischer, A.; Reutter, W.; Danker, K. Glucosamine-glycerophospholipids that activate cell-matrix-adhesion and migration. J. Med. Chem., 2005, 48, 6750.
27. Marino-Albernas, J.R.; Bittman, R.; Peters, A.; Mayhew, E. Synthesis and growth inhibitory properties of glycosides of 1-O-hexadecyl-2-O-methyl-sn-glycerol, analogs of the antitumor ether lipid ET-18-OCH3 (edelfosine). J. Med. Chem., 1996, 39, 3241.
28. Lohmeyer, M.; Bittman, R. Antitumor ether lipids and alkylphosphocholines. Drugs Future, 1994, 19, 1021.
29. Byun, H.-S.; Kumar, E.R.; Bittman, R Enantioselective syntheses of 1-O-benzyl-sn-glycerol and 1-O-hexadecyl-2-O-methyl-sn-glycerol via asymmetric dihydroxylation of allyl 4-methoxyphenyl ether. Use of AD-mix supplemented with potassium persulfate. J. Org. Chem., 1994, 59, 2630.
30. Kumar, E.R.; Byun, H.-S.; Wang, S.; Bittman, R. Preparation of ether-linked 2-acetamido-2-deoxy-β-glycolipids via zinc chloride promoted coupling of Ac GlcNAc-Cl with lipid hydroxy groups. Tetrahedron Lett, 1994, 35, 505.
31. Prinz, H.; Six, L.; Ruess, K-P.; Lieflander, M. Stereoselektiv synthese von langkettigen 1-O-((3-D-maltosyyl)-3-O-alkyl-sn-glycerinen (alkylglyceylether-lysoglycolipide) Liebigs Ann. Chem., 1985, 217.
32. Weber, N.; Benning, H. Synthesis of ether glyceroglycolipids. Chem. Phys. Lipids, 1986, 41, 93.
33. Guivisdalsky, P.N.; Bittman, R.; Smith, Z.; Blank, M.L.; Snyder, F.; Howard, S.; Salari, H. Synthesis and antineoplastic properties of ether-linked thioglycolipids. J. Med. Chem., 1990, 33, 2614.
34. Noseda, A.; Berens, M.E.; Piantadosi, C; Modest, E.J. Neoplastic cell inhibition with new ether lipid analogues. Lipids, 1987, 22, 878.
35. Hermann, D.B.J.; Besenfelder, E.; Bicker, U.; Pahlke, W.; Bohm, E. Pharmacokinetics of the thioether phospholipid analogue BM41.440 in rats, Lipids, 1987, 22, 952.
36. Lu, X.; Rengan, K.; Bittman, R.; Arthur, G. The a and (3 anomers of 1-O-hexadecyl-2-O-methyl-3-S-thioglucosyl-sn-glycerol inhibit the proliferation of epithelial cancer cell lines. Oncol Rep., 1994, 1, 933.
37. Lu, X.; Arthur, G. The differential susceptibility of A427 and A549 cell lines to the growth inhibitory effects of ET-18-OCH3 does not correlate with the relative effects of the alkyl-lysophospholipid on the incorporation of fatty acids into cellular phospholipids. Cancer Res., 1992, 52, 2813.
38. Samadder, P.; Byun, H-S.; Bittman, R.; Arthur, G. An active endocytosis pathway is required for the cytotoxic effects of glycosylated antitumor ether lipids. Anticancer Res., 2011, 31, 3809.
39. Rogan, A.M.; Hamilton, T.C.; Young, R.C.; Klecker, R.W. Jr.; Ozols, R.F. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science, 1984, 224, 994.
40. Green, J.A.; Vistica, D.T.; Young, R.C.; Hamilton, T.C.; Rogan, A.M.; Ozols, R.F.; Potentiation of melphalan cytotoxicity in human cancer cell lines by glutathione depletion. Cancer Res., 1984, 44, 5472.
41. Samadder, P.; Byun, H-S.; Bittman, R.; Arthur, G. Glycosylated antitumor ether lipids are more effective against oncogene-transformed fibroblasts than choline-containing alkyl-lysophospholipids. Anticancer Res., 1998, 18, 465.
42. Bittman, R.; Byun, H-S.; Mercier, B.; Salari, H. Isosteric phosphonate analogues of ET-16-OMe. Synthesis and biological evaluation of the enantiomers of 2'-(trimethylammonio)ethyl 4-(hexadecyloxy)-3-methoxybutanephosphonate and 2'-(trimethyl-ammonio)ethyl 4-(hexadecylthio)-3-methoxybutanephosphonate. J. Med. Chem., 1994, 37, 425.
43. Bittman, R.; Byun, H.S.; Reddy, K.C.; Samadder, P.; Arthur, G. Enantioselective synthesis and antiproliferative properties of an ilmofosine analogue, 2'-(trimethylammonio)ethyl 3-(hexadecyloxy)-2-(methoxy)propyl phosphate. J. Med. Chem., 1997, 40, 1391.
44. Egan, S.; Wright, J.A.; Jarolim, L.; Yanagihara, K.; Bassin, R.H.; Greenberg, A.H. Transformation by oncogenes encoding protein kinases induces the metastatic phenotype. Science, 1987, 238, 202.
45. Andreesen, R.; Modolell, M.; Weltzein, H.U.; Eibl, H.; Common, H.H.; Lohr, G.W.; Munder, P.G. Selective destruction of human leukemic cells by alkyllysophospholipids. Cancer Res., 1978, 38, 3894.
46. Glasser, L.; Somberg, L.R.; Vogler, W.R. Purging murine leukemic marrow with alkyl-lysophospholipids. Blood, 1984, 64, 1288.
47. Andreesen, R.; Modolell, M.; Munder, P.G. Selective sensitivity of chronic myelogenous leukemia cell populations to alkyl-lysophospholipids. Blood, 1979, 54, 519.
48. Storch, J.; Munder, P.G. Increased membrane permeability for an antitumoral alkyl lysophospholipid in sensitive tumor cells. Lipids, 1987, 22, 813.
49. Powis, G.; Seewald, M.J.; Gratas, C.; Elder, D.; Riebow, J.; Modest, E.J. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res., 1992, 52, 2835.
50. Junghahn, I.; Bergmann, J.; Langen, P.; Thun, I.; Vollgraf, C.; Brachwitz, H. Effect of ALP analogues on inositol trisphosphate formation in H184 mammary epithelial cells before and after transfection with v-erb B oncogene. Anticancer Res., 1995, 15, 449.
51. Yang, G.; Franck, R.W.; Byun, H-S.; Bittman, R.; Samadder, P.; Arthur, G. Convergent C-glycolipid synthesis via the Ramberg-Bäcklund reaction: active antiproliferative glycolipids. Org. Lett., 1999, 1, 2149.
52. Yang, G.; Franck, R.W.; Bittman, R.; Samadder, P.; Arthur, G. Synthesis and growth-inhibitory properties of glucosamine-derived glycerolipids. Org. Lett., 2001, 3, 197.
53. Jackson, J.K.; Burt, H.; Mok, W.; Salari, H.; Kumar, E.R.; Byun, H-S.; Bittman, R. A comparison of the lytic properties of two ether-linked lipids, one with and one without antineoplastic activity. Biochem. Cell. Biol., 1994, 72, 297.
54. Slaton, J.W.; Hampton, J.A.; Selma, S.H. Exposure to alkyllysophospholipid inhibits in vitro invasion of transitional cell carcinoma. J. Urol., 1994, 152, 1594.
55. Schallier, D.C.; Bruyneel, E.A.; Storme, G.A.; Hilgard, P.; Mareel, M.M. Antiinvasive activities of hexadecylphosphosphocholine in vitro. Anticancer Res., 1991, 11, 1285.
56. Candal, F.J.; Bosse, D.C.; Vogler, W.R.; Ades, E.W. Inhibition of induced angiogenesis in human microvascular endothelial cell line by ET-18-OCH3. Cancer Chemother. Pharmacol., 1994, 34, 1755.
57. Van Slambrouck, S.; Steelant, W.F.; Lopez, M.; Rechi, M.A.; Boilly-Mare, Y.; Bruyneel, E.A.; Delannoy, P.; Verbert, A.; Van den Eeckhout, E.G.; Deforce, D. Edelfosine projects precultural heart fragments against the invasion of malignant cells through altered sialylation. Oncol Rep., 2007, 17, 433.
58. Vandier, C.; Bougnoux, P.; Chantome, A.; Corbel, B.; Girault, A.; Haelters, J-P.; Joulin, V.; Potier-Cartereau, M.; Simon, G. Method for preventing cancer metastasis. PCT Int. Appl. WO2011/101408.
59. Girault, A.; Haelters, J-P.; Potier-Cartereau, M.; Chantome, A.; Pinault, M.; Marionneau-Lambot, S.; Oullier, T.; Simon, G.; Couthon-Gourves, H.; Jaffres, P.-A.; Corbel, B.; Bougnoux, P.; Joulin, V.; Vandier, C. New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasis. Curr. Cancer Drug Targets, 2011, 11, 1111.
60. Schwab, A.; Hanley, P.; Fabian, A.; Stock, C. Potassium channels keep mobile cells on the go. Physiology, 2008, 23, 212.
61. Chantome, A.; Girault, A.; Potier, M.; Collin, C.; Vaudin, P.; Pages, J-C.; Vandier, C.; Joulin, V. KCa2.3 channel-dependent hyperpolarization increases melanoma cell motility. Exp. Cell. Res., 2009, 315, 3620.
62. Potier, M.; Tran, A.T.; Chantome, A.; Girault, A.; Joulin, V.; Bougnoux, P.; Vandier, C.; Pierre, F. Altered SK3/KCa2.3-mediated migration in adenomatous polyposis coli (Apc) mutated mouse colon epithelial cells. Biochem. Biophys. Res. Commun., 2010, 397, 42.
63. Potier, M.; Joulin, S.; Roger, S.; Besson, P.; Jourdan, M.L.; Leguennec, J.Y.; Bougnoux, P.; Vandier, C. Identification of SK3 channel is a new mediator of breast cancer cell migration. Mol. Cancer Ther., 2006, 5, 2946.
64. Weber, N.; Benning, H. 1986. Topics in Lipid Research from Structural Elucidation to Biological Function. Klein, R., and Schmititz, B., Eds., Royal Society of Chemistry, London., pp. 14-19.
65. Ahmad, I.; Filep, J.J.; Franklin, J.C.; Janoff, A.S.; Masters, G.R.; Pattassery, J.; Peters, A.; Schupsky, J.J.; Zha, Y.; Mayhew, E. Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Cancer Res., 1997, 57, 1915.
66. Busto, J.V; Del Canto-Jañez, E.; Goñi, F.M.; Mollinedo, F.; Alonso, A. Combination of the anti-tumor cell ether lipid edelfosine with sterols abolishes hemolytic side effects of the drug. J. Chem. Biol., 2008, 1, 89.
67. Fleer, E.A.M.; Unger, C.; Kim, D-J.; Eibl, H. Metabolism of ether phospholipids and analogues in neoplastic cells. Lipids, 1987, 22, 856.
68. Lu, X.; Zhou, X.; Kardash, D.; Arthur, G. Metabolism of alkyl lysophospholipid in epithelial cancer cell lines and inhibition of cell growth. Biochem. Cell. Biol., 1993, 71, 122.
69. Weber, N.; Benning, H. Metabolism of ether glycolipids with potentially antineoplastic activity by Ehrlich ascites tumor cells. Biochim. Biophys. Acta, 1988, 959, 91.
70. Wilcox, R.W.; Wykle, R.L.; Schmitt, J.D.; Daniel, L.W. The degradation of platelet-activation factor and related lipids: susceptibility to phospholipase C and D. Lipids, 1987, 22, 800.
71. Vallari, D.S.; Smith, Z.L.; Snyder, F. HL-60 cells become resistant towards antitumor ether-linked phospholipids following differentiation into granulocytic form. Biochem. Biophys. Res. Commun., 1988, 156, 1.
72. Kroemer, G.; Levine, B. Autophagic cell death: The story of a misnomer. Nat. Rev. Mol. Cell. Biol., 2008, 9, 1004.
73. Bröker, L.E.; Kruyt, F.A.E.; Giaccone, G. Cell death independent of caspases: a review. Clin. Cancer Res., 2005, 11, 3155.
74. Tang, P.S.; Mura, M.; Seth, R.; Mingyao, L. Acute lung injury and cell death: how many ways can cells die? Am. J. Physiol. Lung Cell. Mol. Physiol., 2008, 294, L632.
75. Wang, Y.; Dawson, V.L.; Dawson, T.M. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in partanatos. Exp. Neurol., 2009, 218, 193.
76. Kroemer, G.; Galluzzi, L.; Vandenabeele, P.; Abrams, J. et al. Classification of cell death:recommendation of the Nomenclature Committee on cell death. Cell Death Differ., 2009, 16, 3.
77. Golstein, P.; Kroemer, G. Cell death by necrosis: Towards a molecular definition. Trends Biochem. Sci., 2007, 32, 37.
78. McCall, K. Genetic control of necrosis-another type of programmed cell death. Curr. Opin. Cell. Biol., 2010, 22, 882.
79. Mizushima, N.; Levine, B.; Cuervo, A.M.; Klionsky, D.J. Autophagy fights diseases through cellular self digestion. Nature, 2008, 45, 1069.
80. Lamb, C. A.; Yoshimori, T.; Tooze, S.A. The autophagosome: origins unknown, biogenesis complex. Nat. Rev. Mol. Cell. Biol., 2013, 14, 759.
81. Burz, C.; Berindan-Neago, I.; Balacescu, O.; Irimie, A. Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol., 2009, 48, 811.
82. MacFarlane, M. Cell death pathways-potential therapeutic targets. Xenobiotica, 2009, 39, 616.
83. Cory, S.; Adam, J.M. The Bcl-2 family: Regulators of the cellular life-or-death switch. Nat. Rev. Cancer, 2002, 2, 647.
84. Deveraux, Q.L.; Read, J.C. IAP family proteins- suppressors of apoptosis. Genes Dev., 1999, 13, 239.
85. Suzuki, Y.; Takahashi-Niki, K.; Akagi, T.; Hashikawa, T.; Tkahashi, R. Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Diff., 2004, 11, 208.
86. Johansson, A-C.; Appelqvist, H.; Nilsson, C.; Kagedal, K.; Roberg, K.; Ollinger, K. Regulation of apoptosis-associate lysosomal membrane permeabilization. Apoptosis, 2010, 15, 527.
87. Boya, P.; Kroemer, G. Lysosomal membrane permeabilization in cell death. Oncogene, 2008, 27, 6434.
88. Kirkegaard, T.; Jaattela, M. Lysosomal involvement in cell death and cancer. Biochim. Biophys. Acta, 2008, 1793, 746.
89. Boya, P.; Andreau, K.; Poncet, D.; Zamzami, N.; Perfettini, J.L.; Metivier, D.; Ojcius, D.M.; Jaattela, M.; Kroemer, G. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J. Exp. Med., 2003, 197, 1323.
90. Conus, S.; Simon, H-U. Cathepsins: key modulators of cell death and inflammatory responses. Biochem. Pharmacol., 2008, 76, 1374.
91. Turk, B.; Stoka, V. Protease signaling in cell death: Caspases versus cysteine cathepsins. FEBS Lett., 2007, 581, 2761.
92. Bidere, N.; Lorenzo, H.K.; Carmona, S.; Laforge, M.; Harper, F.; Dumont, C.; Senik, A. Cathepsin D triggers Bax activation resulting in selective apoptosis-inducing factor relocation in T lymphocytes entering early commitment phase to apoptosis. J. Biol. Chem., 2003, 278, 31401.
93. Guicciardi, M.E.; Deussing, J.; Miyoshi, H.; Bronk, S.F.; Svingen, P.A.; Peters, C.; Kaufmann, S.H.; Gores, G.J. Cathepsin B contributes to TNF-alpha mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J. Clin. Invest., 2000, 106, 1127.
94. Zhang, H.; Zhong, C.; Shi, L.; Guo, Y.; Fan, Z. Granulysin induces cathepsin B release from lysosomes of target tumor cells to attack mitochondria through processing of Bid leading to necroptosis. J. Immunol., 2009, 182, 6993.
95. Vancompernolle, K.; Van Herreweghe, F.; Pynaert, C.M.; Van de Craen, M.; De Vos, K.; Totty, N.; Sterling, A.; Fiers, W.; Vandenabeele, P.; Grooten, J. Atractyloside-induced release of cathepsin B, a protease with caspase processing activity. FEBS Lett., 1998, 438, 150.
96. Ivanov, A.; Beers, S.A.; Walshe, C.A.; Honeychurch, J.; Alduaij, W.; Cox, K.L.; Potter, K.N.; Murray, S.; Chan, C.H.T.; Klymenko, T.; Erenpreisa, J.; Glennie, M.J.; Illidge, T.M.; Cragg, M.S. Monoclonal antibodies directed to CD20 and HLR-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J. Clin. Invest., 2009, 119, 2143.
97. Alduaij, W.; Ivanov, A.; Honeychurch, J.; Cheadle, E.; Potluri, S.; Lim, S.H.; Shimada, K.; Chan, C.H.; Tutt, A.; Beers, S.A.; Glenie, M.J.; Cragg, M.S.; Illidge, T.M. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent lysosome mediated cell death in B cell malignancies. Blood, 2011, 117, 4519.
98. Rammer, P.; Groth-Pedersen, L.; Kirkegaard, T.; Daugaard, M.; Rytter, A.; Szyniarowski, P.; Hoyer-Hansen, M.; Povlsen, L.K.; Nylandsted, J.; Larsen, J.E.; Jaattela, M. BAMLET activates a lysosomal cell death program in cancer cells. Mol. Cancer Ther., 2010, 9, 24.
99. Bröker, L.E.; Huisman, C.; Ferreira, C.G.; Rodriguez, J.A.; Kruyt, F.A.E.; Giaccone, G. Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilonne B in non-small cell lung cancer cells. Cancer Res., 2002, 62, 4081.
100. Broker, L.E.; Huisman, C.; Span, S.W.; Rodriguez, J.A.; Kruyt, F.A.E.; Giaccone, G. Cathepsin B mediates caspase independent cell death induced by microtubule stabilizing agents in non-small lung cancer cells. Cancer Res., 2004, 64, 27.
101. Huisman, C.; Ferreira, C.G.; Bröker, L.E.; Rodriguez, J.A.; Kruyt, F.A.E.; Giaccone, G. Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin. Cancer Res., 2002, 8, 596.
102. Gajate, C.; Santos-Beneit, A.; Modolell, M.; Mollinedo, F. Involvement of c-Jun NH2-terminal kinase activation and c-jun in the induction of apoptosis by the ether lipid 1-O-octadecyl-2-O-methyl-rac-glycerophosphocholine. Mol. Pharmacol., 1998, 53, 602.
103. Jackson, J.K.; Burt, H.M.; Oktaba, A.M.; Hunter, W.; Scheid, M.P.; Mouhajir, F.; Lauemer, R.W.; Shen, Y.; Salari, H.; Duronio, V. The antineoplastic ether lipid S-phosphonate selectively induces apoptosis in human leukemia cells and exhibits antiangiogenic and apoptotic activity on the chorioallantoic membrane of the chick embryo. Cancer Chemother. Pharmacol., 1998, 41, 326.
104. Mollinedo, F.; Gajate, C.; Martin-Santamaria, S.; Gago, F. ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr. Med. Chem., 2004, 11, 3163.
105. Ruiter, G.A.; Zerp, S.F.; van Blitterswijk, W.J.; Verheij, M. Alkyllysophospholipids activate the SAPK/JNK pathway and enhance radiation induced apoptosis. Cancer Res., 1999, 59, 2457.
106. Zhou, X.; Lu, X.; Richard, C.; Xiong, W.; Litchfield, D.W.; Bittman, R.; Arthur, G. 1-O-Octadecyl-2-O-methylglycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in MCF-7 cells. J. Clin. Invest., 1996, 98, 937.
107. Samadder, P.; Bittman, R.; Byun, H-S.; Arthur, G. Synthesis and use of novel ether phospholipids enantiomers to probe the molecular basis of the antitumor effects of alkyllysophospholipids: correlation of differential activation of c-Jun-NH2-terminal protein kinase with antiproliferative effects in neuronal tumor cells. J. Med. Chem., 2004, 47, 2710.
108. Arthur, G.; Samadder, P.; Bittman, R. ET18-OCH3 inhibits the phosphorylation and activation of p70 S6 kinase in MCF-7 cells. Anticancer Res., 1995, 25, 95.
109. Samadder, P.; Bittman, R.; Byun, H-S.; Arthur, G. A glycosylated antitumor ether lipid kills cells by a paraptosis-like cell death. Biochem. Cell. Biol., 2009, 87, 401.
110. Jahreiss, L.; Renna, M.; Bittman, R.; Arthur, G.; Rubinsztein, D.C. 1-O-Hexadecyl-2-O-methyl-3-O-(2"-acetamido-2"-deoxy-β-D-glucopyranosyl)-sn-glycerol (Gln) induces cell death with more autophagosomes which is autophagy-independent. Autophagy, 2009, 5, 835.
111. Susin, S.A.; Zamzami, N.; Castedo M.; Hirsch, T.; Marchetti, P.; Macho, A.; Daugas, E.; Geuskens, M.; Kroemer, G. Bcl2 inhibits mitochondrial release of apoptogenic protease. J. Exp. Med., 1996, 184, 1331.
112. Mizushima, N.; Yamamoto, A.; Hatano, M.; Kobayashi, Y.; Kabeya, Y.; Suzuki, K.; Tokuhisa, T.; Ohsumi, Y.; Yoshimori, T. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J. Cell. Biol., 2001, 152, 657.
113. Takahashi, Y.; Coppola, D.; Mattsushita, N.; Cualing, H.D.; Sun, M.; Sato, Y.; Liang, C.; Jung, J.U.; Cheng, J.Q.; Mule, J.J.; Pledger, W.J.; Wang, H.G. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat. Cell. Biol., 2007, 9, 1142.
114. Nishida, Y.; Arakawa, S.; Fujitani, K.; Yamaguchi, H.; Mizuta, T.; Kanaseki, T.; Komatsu, M.; Otsu, K.; Tsujimoto, Y.; Shimizu, S. Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature, 2009, 461, 654.
115. Shimuzi, S.; Arakawa, S.; Nishida, Y. Autophagy takes an alternative pathway. Autophagy, 2010, 6, 290.
116. Klionsky, D.J.; Lane, J.D. Alternative macroautophagy. Autophagy, 2010, 6, 201.
117. Hayashi-Nishino, M.; Fujita, N.; Noda, T.; Yamaguchi, A.; Yoshimori, T.; Yamamoto, A. A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation. Nat. Cell Biol., 2009, 11, 1433.
118. Yla-Anttila, P.; Vihinen, H.; Jokitalo, E.; Eskelinen, E.L. 3D tomography reveals connection between the phagophore and endoplasmic reticulum. Autophagy, 2009, 5, 1180.
119. Hailey, D.W. et al. Mitochondria supply membranes for autophagosome biogenesis during starvation. Cell, 2010, 141, 656.
120. Wiczling, P.; Kawczak, P.; Nasal, A.; Kalszan, R. Simultaneous determination of pKa and lipophilicity by gradient RP HPLC. Anal. Chem., 2006, 78, 239.
121. Andrew, C.L.; Klemm, A.R.; Lloyd, J.B. Lysosome membrane permeability to amines. Biochim. Biophys. Acta, 1997, 1330, 71.
122. Ivanov, A.I. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? Methods Mol. Biol., 2008, 440, 15.
123. Kuronita, T.; Eskelinen, E-L.; Fujita, H.; Saftig, P.; Himeno, M.; Tanaka, Y. A role for the lysosomal protein LGP85 in the biogenesis and maintenance of endosomal lysosomal morphology. J. Cell Sci., 2002, 115, 4117.
124. Punnonen, E-L.; Ryhanen, K.; Marjomaki, V. At reduced temperature, endocytic membrane traffic is blocked in multivesicular carrier endosomes in rat cardiac myocytes. Eur. J. Cell Biol., 1998, 75, 344.
125. Casiola-Rosen, L.A.; Hubbard, A.L. Lumenal labeling of rat hepatocyte early endosomes. J. Biol. Chem., 1992, 267, 8213.
126. Dunn, W.A.; Hubbard, A.L.; Aronson, N.A. Low temperature selectively inhibits fusion between pinocytic vesicles and lysosomes during heterophagy of 125I-asialofetuin by the perfuse rat liver. J. Biol. Chem., 1980, 255, 5971.
127. Sullivan, P.C.; Ferris, A.L.; Storrie, B. Effects of temperature, pH elevators, and energy production inhibitors on horseradish peroxidase transport through endocytic vesicles. J. Cell. Physiol., 1987, 131, 58.
128. Ono, K.; Kim, S.O.; Han, J. Susceptibility of lysosomes to rupture is a determinant for plasma membrane disruption in tumor necrosis factor alpha-induced cell death. Mol. Cell. Biol., 2003, 23, 665.
129. Al-Hajj, M.; Wicha, M.S.; Weissman, I.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA, 2003, 100, 3983.
130. Collins, A.T.; Berry, P.A.; Hyde, C.; Stower, M.; Maitlan, N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res., 2005, 65, 10946.
131. O'Brien, C.; Pollet, A.; Gallinger, S.; Dick, J.E. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature, 2007, 445, 106.
132. Li, C.; Heidt, D.G.; Dalerba, P.; Burant, C.F.; Zhang, L.; Adsav, V.; Wicha, M.; Clarke, M.F.; Simeone, D.M. Identification of pancreatic cancer stem cells. Cancer Res., 2007, 67, 1030.
133. Pan, Y.; Huang, X. Epithelial ovarian cancer stem cells - a review. Int. J. Clin. Exp. Med., 2008, 1, 260.
134. Lobo, N.A.; Shimono, Y.; Qian, D.; Clarke, M.F. The biology of cancer stem cells. Ann. Rev. Cell. Dev. Biol., 2007, 23, 41.
135. Besancon, R.; Valsesia-Wittman, S.; Puisieux, A.; De Fromental, C.C.; Maguer-Satta, V. Cancer stem cells: emerging challenge of drug targeting. Curr. Med. Chem., 2009, 16, 394.
136. Frank, N.Y.; Schatton, T.; Frank, M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest., 2010, 120, 41.
137. Glunde, K.; Guggino, S.E.; Solaiyappan, M.; Pathak, A.P.; Ichikawa, Y.; Bhujwalla, Z.M. Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia, 2003, 5, 533.